Moonwalk Biosciences, Inc.
moonwalk.bio
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
201-500
employees, estimated range
Backers
1
ARCH Venture Partners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
ARCH Venture Partners Similar startupsby what they do, their industry and backers
Advancing reversible therapies targeting von Willebrand Factor for safer treatment of acute thrombotic conditions. Precision control when…
Format analyzes every customer conversation and finds insights just for you.. By deeply understanding you and your company, Format analyzes…
Automation Intellect was developed to fundamentally change manufacturing’s approach to managing machine performance with the goal of…
Cellino is a Massachusetts biotechnology company founded in 2017. It automates stem cell manufacturing with laser editing, imaging and…
Sprocket Security was founded to improve the way we approach cybersecurity. Currently the industry performs services in a timeboxed, or…
Aviwell aims to nourish the planet with sustainable microbiota-based solutions. At a fraction of the cost..
News
Pharmaceutical Executive Daily: Moonwalk Biosciences
Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its fat-targeted obesity platform, and Sebastian Arana of MilliporeSigma talks through the real cost of manuf
Read more
Report
Finding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D.
On this weeks episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s.
Read more
Report
Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today
Read more
Report
Moonwalk Biosciences Raises $70 Million Series B To Advance Adipose-Targeted RNAi Obesity Therapies
Moonwalk Biosciences has raised an oversubscribed $70 million Series B financing to advance its pipeline of adipose-targeted RNA interference medicines for obesity and cardiometabolic diseases. The round was co-led by Alpha Wave and YK Bioventures, with p
Read more
Report
Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases
SOUTH SAN FRANCISCO & SAN DIEGO, September 08, 2026--Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases
Read more
Report
Pro access
Upgrade to see all 13 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.